Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2012

View Archived Issues

New Wnt/catenin beta signaling inhibitor shows potential as cancer therapy

Durable submental fat reduction seen with ATX-101

Novel mTOR inhibitors reported

Merck KGaA develops novel inhibitors of tyrosine-protein kinases

GSK discloses new chemokine CCR4 receptor antagonists

U.S. university presents new vaccines for dengue

Peptide vaccine to enter phase IIa study

Hyperion Therapeutics acquires rights to Ravicti

Bioabsorbable stent shows promise in patients with coronary artery disease

Toray evaluates 11-beta-HSD1 inhibitor in obesity and diabetes models

New product extends therapeutic window of t-PA in stroke model

Coronado Biosciences signs agreement with Dr. Falk Pharma and OvaMed

GSK and Theravance complete registrational program

Byetta obtains European approval as add-on therapy to basal insulin

Medgenics receives clearance for phase IIa study in patients on dialysis

Mitsubishi Tanabe revises prescribing information for Imusera

NeuroDiscovery provides company update

Applications submitted for once-monthly risedronate sodium hydrate in Japan

Novel FLAP and leukotriene synthesis inhibitors patented

NeoPharm presents new protease-activated PAR2 receptor antagonists

Bionomics clear to initiate phase I/II trial of BNC-105

Kyorin Pharmaceutical reports novel AMPK activators

Pivotal LEAP trial reaches target enrollment

Endocyte receives approval for nonproprietary names of anticancer drug and companion imaging agent

EMA validates Raptor's MAA for RP-103

EMA to review Vivus' MAA for avanafil in ED

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...